Drugs / Low-dose aspirin
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy3 trials | ||||||
| Phase 2 | NCT04182100 Background | Dec 2019 → Mar 2021 | acquired polycythemia vera | PharmaEssentia Japan K.K. | Completed | No outcome recorded |
| Phase 3 | NCT06002490 Background | Oct 2023 → Jul 2024 | acquired polycythemia vera | PharmaEssentia Japan K.K. | Completed | No outcome recorded |
| — | NCT04228263 Background | Jan 2020 → Mar 2023 | pregnancy loss, recurrent, 4 | Assiut University | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Low-dose aspirin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06002490 ↗ |
| Known as | acetylsalicylic acid | “Low-dose aspirin (acetylsalicylic acid) (75-150 mg/day) will be given as background therapy during the 12 months of study treatment, unless contraindicated.” NCT06002490 ↗1“Low-dose aspirin (acetylsalicylic acid) (75-150 mg/day) will be given as background therapy during the 12 months of study treatment, unless contraindicated.” NCT04182100 ↗ |